Emi Hosaka

This inventor holds 39 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 3 EPO patents, primarily in Antibody Engineering. Top assignees: Kyowa Hakko Kirin Co., Limited, Kyowa Hakko Kogyo Co., Ltd., National Cancer Center. Active years: 2005-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Emi Hosaka. Retrieved from https://idiyas.com/inventor/emi-hosaka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 39 (Patent Applications = 6)

% Patents Active = 33.3

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 8.0

ph-index = 16

Forward Citations = 845(Granted Patents)

Location History:

Tokyo, JP (2008)
Chiyoda-ku, JP (2012)
Stuttgart, DE (2012)
Machida, JP (2005 - 2020)

Company Filing History:

31 out of 272

Kyowa Hakko Kirin Co., Limited

patents

7 out of 730

Kyowa Hakko Kogyo Co., Ltd.

patents

2 out of 264

National Cancer Center

patents

4. 1 out of 46

Kyowa Kirin Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2005-2020

Loading Chart...

Areas of Expertise:

CDR-Grafted Antibody

Glycoengineered Antibody

Antibody Composition

Immune Modulation

Cellular Cytotoxicity

Fucosylation

ADCC

RNAi

Antibody Production

Her-2

Interleukin-5

CXCR4

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10590203 - Human CDR-grafted antibody and antibody fragment thereof (2020-03-17),

2. 10233475 - Antibody composition-producing cell (2019-03-19),

3. 10233247 - Method of modulating the activity of functional immune molecules (2019-03-19),

4. 10131711 - Human CDR-grafted antibody and antibody fragment thereof (2018-11-20),

5. 9409982 - Antibody composition-producing cell (2016-08-09),

6. 9051371 - Human CDR-grafted antibody and antibody fragment thereof (2015-06-09),

7. 8900584 - Human CDR-grafted antibody and antibody fragment thereof (2014-12-02),

8. 8895266 - Antibody composition-producing cell (2014-11-25),

9. 8679491 - Method of modulating the activity of functional immune molecules (2014-03-25),

10. 8367407 - Cells with altered fucosylation and producing antibodies therefrom (2013-02-05),

11. 8329443 - Antibody composition-producing cell (2012-12-11),

12. 8158760 - Glycoengineered, recombinant antibody (2012-04-17),

13. 8143058 - Human CDR-grafted antibody and antibody fragment thereof (2012-03-27),

14. 8110195 - Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody (2012-02-07),

15. 8101185 - Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation (2012-01-24),

Title: The Innovative Journey of Emi Hosaka

Introduction: Emi Hosaka, a pioneering inventor hailing from Machida, Japan, has made significant contributions to the world of innovations with his groundbreaking ideas and inventions.

Latest Patents: Emi Hosaka's latest patents include cutting-edge technologies in the field of robotics and artificial intelligence, showcasing his continuous commitment to pushing the boundaries of technological advancements.

Career Highlights: Throughout his illustrious career, Emi Hosaka has been recognized for his inventive spirit and problem-solving skills. His inventions have revolutionized various industries, from healthcare to automotive, leaving a lasting impact on the world.

Collaborations: Emi Hosaka has collaborated with leading research institutions and universities to further his innovative projects. His partnerships with top-notch scientists and engineers have resulted in the development of cutting-edge solutions that have the potential to shape the future.

Conclusion: Emi Hosaka's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his position as a visionary inventor in the global landscape of technology and inventions.

Profile summary based on public USPTO records.